Efficacy of nebivolol on flow-mediated dilation in patients with slow coronary flow

International Heart Journal

Volumn 50, Issue 5, 2009, Pages 545-553

  Albayrak, Sinan ^a   Ordu, Serkan ^a   Yuksel, Hatice ^a   Ozhan, Hakan ^a   Yazgan, Ömer ^a   Yazici, Mehmet ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

Coronary slow flow; Nebivolol

Indexed keywords

C REACTIVE PROTEIN; GLYCERYL TRINITRATE; NEBIVOLOL;

ARTICLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; SLOW CORONARY FLOW; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-ANTAGONISTS; AGED; BENZOPYRANS; CHEST PAIN; CORONARY ANGIOGRAPHY; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASODILATION;

EID: 74849117353     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.545     Document Type: Article

References (19)

1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries - a new angiographic finding. Am Heart J 1972; 84: 66-71.
2. Singh S, Kothari SS. Bahl VK. Coronary slow flow phenomenon: an angiographic curiosity. Indian Heart J 2004; 56: 613-7. (Review)
3. Sezgin AT, Sigirci A, Barutcu I, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003; 14: 155-61.
4. Turhan H, Saydam GS, Erbay AR, et al. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol 2006; 108: 224-30.
5. Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, Horowitz JD. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol 2004; 44: 57-62.
6. Fam WM, McGregor M. Effect of nitroglycerin and dipyridamole on regional coronary resistance. Circ Res 1968; 22: 649-59.
7. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71.
8. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88.
9. Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 2001; 157: 369-73.
10. Welsch MA, Allen JD, Geaghan JP. Stability and reproducibility of brachial artery flow-mediated dilation. Med Sci Sports Exerc 2002; 34:960-5.
11. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flew-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005; 127: 2254-63. (Review)
12. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000; 102: 677-84.
13. Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivatives increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003; 42: 1838-44.
14. Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005; 19: 277-81.
15. Korkmaz H, Karaca I, Koç M, Onalan O,Yilmaz M, Bilen MN. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. Endothelium 2008; 15: 149-55.
16. Staub D, Meyerhans A, Bundi B, Schmid HP, Frauchiger B. Prediction of cardiovascular morbidity and mortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness. Stroke 2006; 37: 800-5.
17. Berk BC, Weintroub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-72.
18. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.
19. Caliskan M, Erdogan D, Gullu H, et al. Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow. Clin Cardiol 2007; 30:475-9.